Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis.

Efficacy of nucleoside analogues for hepatitis B virus-related liver failure: A network meta-analysis.
Acta Pharm. 2018 Mar 01;68(1):19-30
Authors: Wu J, Yin F, Zhou X
Abstract
The purpose of this study was to compare the efficacy of nucleoside analogues (NAs) in the treatment of HBV-related liver failure. The data of patients with HBV-related liver failure treated with nucleoside analogues were used to conduct a network meta-analysis. A total of 1660 patients from 12 articles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for HBV-related liver failure treatment were recruited in the study. The highest two- and three-month survival rate was recorded for patients using tenofovir. The end-stage liver disease (MELD) score and mortality in patients undergoing tenofovir treatment were the lowest. Patients treated with telbivudine had the highest one-month survival rate. Patients receiving enticavir therapy showed the lowest HBV DNA level. Our results indicate that tenofovir may be the best therapy for the treatment of HBV-related liver failure compared to other nucleoside analogues (including lamivudine, entecavir and telbivudine) and non-NAs treatment.
PMID: 29453915 [PubMed - in process]

Source: Acta Pharmaceutica - February 19, 2018 Category: Drugs & Pharmacology Authors: Wu J, Yin F, Zhou X Tags: Acta Pharm Source Type: research